• Explore /
  • Poster
  • / A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).

A secondary analysis of PSA response in NRG Oncology/RTOG 9902: A phase III trial of adjuvant chemotherapy with androgen suppression and radiation for high-risk prostate cancer (CaP).

Abstract Poster

Authors

null

Stephen Andrew Mihalcik

Harvard Radiation Oncology Residency Program, Massachusetts General Hospital, Boston, MA

Stephen Andrew Mihalcik , Meredith M. Regan , Seth A. Rosenthal , Glenn J. Bubley , Kenneth J. Pienta , Leonard G. Gomella , David A. Grignon , Alan C Hartford , Mark S. Morginstin , Jeff M. Michalski , Raghu Rajan , Andrew Michael McDonald , Michael M. Dominello , James Norman Atkins , Christopher U Jones , Jennifer Moughan , Howard M. Sandler , Irving D. Kaplan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer–Local-Regional Disease

Citation

J Clin Oncol 35, 2017 (suppl; abstr 5078)

DOI

10.1200/JCO.2017.35.15_suppl.5078

Abstract #

5078

Poster Bd #

152

Abstract Disclosures

Similar Posters

First Author: Ryan Phillips

First Author: Abdenour Nabid

First Author: Mamta Parikh

First Author: Fred Saad